MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-11-2023
Surgalign Holdings EPS Ratio 2011-2026 | SRGA
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Surgalign Holdings
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -8.33 | -20.7 | -0.45 | -3.02 | -0.09 | 0.06 | -0.3 | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 0.06 | -20.7 | -4.69 |
Quarterly EPS Ratio Surgalign Holdings
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.51 | - | -1.46 | -0.86 | - | - | -1.71 | -4.25 | -0.15 | -1.28 | 1.68 | -0.53 | -0.25 | -2.72 | -0.07 | - | -0.15 | 0.01 | 0.05 | -0.11 | -0.03 | -0.13 | 0.28 | -0.04 | -0.05 | - | -0.08 | -0.04 | 0.02 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.68 | -4.25 | -0.473 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Medical devices industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
EDAP TMS S.A.
EDAP
|
-0.51 | $ 3.22 | -2.57 % | $ 121 M |  France |
 |
Align Technology
ALGN
|
5.63 | $ 189.61 | -0.56 % | $ 14.2 B |  USA |
 |
AdaptHealth Corp.
AHCO
|
-0.52 | $ 12.8 | 0.55 % | $ 1.73 B | USA |
 |
Allied Healthcare Products
AHPI
|
-0.48 | - | 3.58 % | $ 2.21 M | USA |
 |
BioSig Technologies
BSGM
|
-9.65 | - | 37.08 % | $ 85.7 M | USA |
 |
Avinger
AVGR
|
-23.3 | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
-1.28 | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
1.29 | - | 1.37 % | $ 20.5 M | USA |
 |
BIOLASE
BIOL
|
-29.4 | - | -13.19 % | $ 166 K | USA |
 |
Conformis
CFMS
|
-6.99 | - | - | $ 16.4 M | USA |
 |
Cytosorbents Corporation
CTSO
|
-0.13 | $ 0.63 | -3.04 % | $ 39.2 M | USA |
 |
Apollo Endosurgery
APEN
|
-0.98 | - | - | $ 475 M | USA |
 |
Cardiovascular Systems
CSII
|
-0.94 | - | 0.15 % | $ 844 M | USA |
 |
ClearPoint Neuro
CLPT
|
-0.9 | $ 11.78 | 9.58 % | $ 334 M | USA |
 |
Dynatronics Corporation
DYNT
|
-1.43 | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
-39.7 | - | - | $ 10.2 M | USA |
 |
Electromed
ELMD
|
0.89 | $ 26.39 | 3.57 % | $ 223 M | USA |
 |
Second Sight Medical Products
EYES
|
-0.43 | - | -0.97 % | $ 54.4 M | USA |
 |
GBS
GBS
|
-2 | - | -0.57 % | $ 7.12 M | USA |
 |
Globus Medical
GMED
|
3.98 | $ 94.87 | 0.52 % | $ 12.8 B | USA |
 |
Helius Medical Technologies
HSDT
|
-14.6 | $ 2.16 | 4.85 % | $ 1.31 M | USA |
 |
Butterfly Network
BFLY
|
-0.34 | $ 5.33 | 3.5 % | $ 1.13 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-1.69 | $ 16.19 | -0.12 % | $ 380 M | USA |
 |
LivaNova PLC
LIVN
|
-4.45 | $ 64.2 | -1.45 % | $ 3.5 B |  Britain |
 |
LENSAR
LNSR
|
-2.87 | $ 5.09 | -3.23 % | $ 60.9 M | USA |
 |
Pulmonx Corporation
LUNG
|
-1.33 | $ 1.27 | -0.78 % | $ 51.7 M | USA |
 |
Delcath Systems
DCTH
|
0.08 | $ 10.84 | 1.88 % | $ 388 M | USA |
 |
IRIDEX Corporation
IRIX
|
-0.26 | $ 1.06 | 0.95 % | $ 18 M | USA |
 |
CONMED Corporation
CNMD
|
1.52 | $ 38.34 | 2.24 % | $ 1.19 B | USA |
 |
Inspire Medical Systems
INSP
|
4.95 | $ 56.31 | -0.07 % | $ 1.65 B | USA |
 |
Integer Holdings Corporation
ITGR
|
2.96 | $ 86.02 | 1.37 % | $ 2.99 B | USA |
 |
PAVmed
PAVM
|
-5.63 | $ 9.0 | -1.85 % | $ 6.03 M | USA |
 |
Invacare Corporation
IVC
|
-0.54 | - | - | $ 24.7 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.84 | $ 84.15 | 5.56 % | $ 49.2 B | USA |
 |
MiMedx Group
MDXG
|
0.33 | $ 3.43 | 2.39 % | $ 507 M | USA |
 |
Nevro Corp.
NVRO
|
-3.06 | - | - | $ 217 M | USA |
 |
Myomo
MYO
|
-0.37 | $ 0.82 | 5.52 % | $ 34.3 M | USA |
 |
TELA Bio
TELA
|
-0.83 | $ 0.7 | 12.54 % | $ 32.9 M | USA |
 |
Cutera
CUTR
|
-2.87 | - | -10.19 % | $ 1.99 M | USA |